Asset Details
Do you wish to reserve the book?
TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation
Do you wish to request the book?
TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation
2019
Overview
Although treatment of chronic myeloid leukemia (CML) has improved with the development of tyrosine kinase inhibitors (TKIs), patients develop fatal blast crisis (BC) whilst receiving TKI treatment. Alternative treatments for cases resistant to TKIs are required. A serine/threonine protein kinase, T-lymphokine-activated killer cell-originated protein kinase (TOPK), is highly expressed in various malignant tumors. Binding of peptides to human leukocyte antigen was assessed via mass spectrometry in K562 CML cells. TOPK expression was assessed in various CML cell lines and in clinical samples obtained from patients with CML using reverse transcription-quantitative polymerase chain reaction and western blot assays. It was observed that TOPK was expressed abundantly in BCR/ABL-positive cell lines and at significantly higher levels in CML clinical samples compared with healthy donor samples. Overexpression of BCR/ABL or the presence of its inhibitor imatinib upregulated and downregulated TOPK expression, respectively, indicating that TOPK may be a target of BCR/ABL. TOPK inhibitor OTS514 suppressed proliferation of BCR/ABL-positive cell lines and colony formation of CD34-positive cells from patients with CML compared with lymphoma patients without bone marrow involvement. Furthermore, phosphorylation of TOPK was increased by protein phosphatase 2A (PP2A) inhibitor okadaic acid and was decreased in the presence of PP2A activator FTY720 compared with untreated samples. As constitutive BCR/ABL activity and inhibition of PP2A are key mechanisms of CML development, TOPK may be a crucial signaling molecule for this disease. Inhibition of TOPK may control disease status of CML, even in cases resistant to TKIs.
Publisher
Spandidos Publications,D.A. Spandidos,Spandidos Publications UK Ltd
Subject
/ Aged
/ Antigens
/ B cells
/ BCR/ABL
/ Female
/ Gene Expression Regulation, Neoplastic
/ Humans
/ Kinases
/ Leukemia
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ Male
/ Mitogen-Activated Protein Kinase Kinases
/ Patients
/ Peptides
/ Phenols (Class of compounds)
/ Plasmids
/ Proteins
/ Studies
/ T-lymphokine-activated killer cell-originated protein kinase
/ T-lymphokine-activated killer cell-originated protein kinase inhibitor
/ Tumors
/ Tyrosine
